This is a preprint.
Microbiome-based risk prediction in incident heart failure: a community challenge
- PMID: 37873403
- PMCID: PMC10593042
- DOI: 10.1101/2023.10.12.23296829
Microbiome-based risk prediction in incident heart failure: a community challenge
Abstract
Heart failure (HF) is a major public health problem. Early identification of at-risk individuals could allow for interventions that reduce morbidity or mortality. The community-based FINRISK Microbiome DREAM challenge (synapse.org/finrisk) evaluated the use of machine learning approaches on shotgun metagenomics data obtained from fecal samples to predict incident HF risk over 15 years in a population cohort of 7231 Finnish adults (FINRISK 2002, n=559 incident HF cases). Challenge participants used synthetic data for model training and testing. Final models submitted by seven teams were evaluated in the real data. The two highest-scoring models were both based on Cox regression but used different feature selection approaches. We aggregated their predictions to create an ensemble model. Additionally, we refined the models after the DREAM challenge by eliminating phylum information. Models were also evaluated at intermediate timepoints and they predicted 10-year incident HF more accurately than models for 5- or 15-year incidence. We found that bacterial species, especially those linked to inflammation, are predictive of incident HF. This highlights the role of the gut microbiome as a potential driver of inflammation in HF pathophysiology. Our results provide insights into potential modeling strategies of microbiome data in prospective cohort studies. Overall, this study provides evidence that incorporating microbiome information into incident risk models can provide important biological insights into the pathogenesis of HF.
Conflict of interest statement
Conflict of Interest Illumina, Inc., and Janssen Pharmaceutica provided additional support by sponsoring the Center for Microbiome Innovation at the University of California San Diego. T.N. has received honoraria for speaking engagements from Servier and AstraZeneca. V.S. has had research collaboration with Bayer AG, unrelated to this study. J.S.-R. has received funding from GSK, Pfizer and Sanofi, and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer and Grunenthal. M.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has a research collaboration with AstraZeneca unrelated to this study. R.K. is a cofounder of Micronoma and Biota, holding stock for Gencirq, Cybele, Biomesense, Micronoma, and Biota, serve as a member of the Scientific Advisory Board in Gencirq, DayTwo, Biomesense, and Micronoma and serve as consultant for DayTwo, Cybele, and Biomesense.
Figures
References
-
- Vaduganathan M., Mensah G. A., Turco J. V., Fuster V. & Roth G. A. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J. Am. Coll. Cardiol. 80, 2361–2371 (2022). - PubMed
-
- Savarese G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 118, 3272–3287 (2023). - PubMed
-
- Bayes-Genis A. et al. Omics phenotyping in heart failure: the next frontier. Eur. Heart J. 41, 3477–3484 (2020). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous